Description of Medical ServiceImlifidase is a treatment used to prevent the body from rejecting a newly transplanted kidney. It is used before transplantation in people who have antibodies against the donor kidney and are considered ’highly sensitised’ based on a positive crossmatch test. It is a desensitisation treatment, used to convert people from crossmatch positive, to negative and therefore reducing the likelihood of the recipient's body rejecting the donated kidney.
Description of Medical ConditionEnd-stage kidney disease is defined by partial or completely failed kidney function. Patients require regular dialysis or a kidney transplant for survival.
Reason for ApplicationHighly Specialised Therapy- National Health Reform Agreement
Medical Service TypeTherapeutic technology
Previous Application Number/sNot Applicable
Application FormApplication Form (PDF 2033 KB)
Application Form (Word 1634 KB)
Consultation SurveyConsultation Survey (PDF 658 KB)
Consultation Survey (Word 27 KB)
PASC consultation closed
MSAC consultation input must be received by no later than Friday, 9 June 2023 for it to be considered by MSAC at its July 2023 meeting.
For further information please refer to PASC, ESC, MSAC Key Dates
For further information on the consultation process please refer to MSAC Consultation Process
PICO ConfirmationPICO Confirmation (PDF 1890 KB)
PICO Confirmation (Word 1104 KB)